Rahdan Shaghayegh, Razavi Seyed Alireza, Nazari Mahboobeh, Shojaeian Sorour, Shokri Fazel, Amiri Mohammad Mehdi, Ramezani Amin, Zarnani Amir-Hassan
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Avicenna J Med Biotechnol. 2022 Jan-Mar;14(1):61-69. doi: 10.18502/ajmb.v14i1.8171.
Placenta-specific 1 (PLAC1) is one of the recently-discovered Cancer-Testis-Placenta (CTP) antigen with restricted normal tissue and ectopic expression in a wide range of cancer cells from different histological origins. The production of recombinant human PLAC1 has already been optimized; however, no study has been reported so far on the production and purification of mouse plac1. In this study, mouse plac1 expression and purification was optimized in a prokaryotic system and the effects of the generated proteins on inducing humoral responses in mice were investigated.
A fusion protein containing full extracellular domain of mouse plac1, immunostimulatory peptides, tetanus toxin P2P30 and PADRE and KDEL3 signal (main plac1), and the same fragment without immunostimulatory peptides (control plac1) was produced. To optimize production and purification steps, different parameters including bacterial strain, cultivation temperature, cultivation time, IPTG concentration, culture medium, and also different buffers for purification of the recombinant proteins were tested. After confirming the identity of recombinant plac1 proteins with Western Blotting (WB) and ELISA assays, these proteins were subcutaneously injected in mice with Freund's adjuvant and the anti-plac1 antibody response was detected by ELISA.
The optimal expression level of main and control plac1 was obtained in BL21 (DE3) and TB culture medium in the presence of 0.25 IPTG after 24 of induction at 15°. The buffer containing 2% sarkosyl produced higher yield and purity. Our results showed specific reactivity of anti-human recombinant plac1 polyclonal antibody with both main and control plac1 recombinant proteins in WB and ELISA analysis. Both proteins induced humoral responses in mice; however, anti-plac1 antibody titer was significantly higher in sera of mice immunized with main compared to control plac1.
In this study, an optimized protocol for production and purification of mouse plac1 was reported and it was shown that insertion of immunostimulatory peptides in gene construct could efficiently enhance humoral immune responses against mouse plac1, which could potentially augment cellular immune responses against plac1 leading to more effective anti-cancer responses.
胎盘特异性1(PLAC1)是最近发现的癌-睾丸-胎盘(CTP)抗原之一,在正常组织中表达受限,在来自不同组织学起源的多种癌细胞中异位表达。重组人PLAC1的生产已经得到优化;然而,迄今为止尚未有关于小鼠plac1生产和纯化的研究报道。在本研究中,在原核系统中优化了小鼠plac1的表达和纯化,并研究了所产生的蛋白质对诱导小鼠体液反应的影响。
制备了一种融合蛋白,其包含小鼠plac1的完整胞外结构域、免疫刺激肽、破伤风毒素P2P30和PADRE以及KDEL3信号(主要plac1),以及不含免疫刺激肽的相同片段(对照plac1)。为了优化生产和纯化步骤,测试了不同参数,包括细菌菌株、培养温度、培养时间、IPTG浓度、培养基,以及用于重组蛋白纯化的不同缓冲液。在通过蛋白质印迹法(WB)和酶联免疫吸附测定(ELISA)确认重组plac1蛋白的身份后,将这些蛋白与弗氏佐剂皮下注射到小鼠体内,并通过ELISA检测抗plac1抗体反应。
在15°诱导24小时后,在含有0.25 mM IPTG的BL21(DE3)和TB培养基中获得了主要plac1和对照plac1的最佳表达水平。含有2% Sarkosyl的缓冲液产生了更高的产量和纯度。我们的结果显示,在WB和ELISA分析中,抗人重组plac1多克隆抗体与主要plac1和对照plac1重组蛋白均具有特异性反应性。两种蛋白均能诱导小鼠产生体液反应;然而,与对照plac1相比,用主要plac1免疫的小鼠血清中的抗plac1抗体滴度显著更高。
在本研究中,报道了一种优化的小鼠plac1生产和纯化方案,结果表明在基因构建体中插入免疫刺激肽可以有效地增强针对小鼠plac1的体液免疫反应,这可能会增强针对plac1的细胞免疫反应,从而导致更有效的抗癌反应。